Currently, there are 210.29M common shares owned by the public and among those 199.72M shares have been available to trade.
The company’s stock has a 5-day price change of 25.19% and 11.56% over the past three months. AKBA shares are trading 32.26% year to date (YTD), with the 12-month market performance up to 97.61% higher. It has a 12-month low price of $0.78 and touched a high of $2.48 over the same period. AKBA has an average intraday trading volume of 1.59 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 22.71%, 17.67%, and 18.58% respectively.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Institutional ownership of Akebia Therapeutics Inc. (NASDAQ: AKBA) shares accounts for 24.20% of the company’s 210.29M shares outstanding.
It has a market capitalization of $344.88M and a beta (3y monthly) value of 0.77. The earnings-per-share (ttm) stands at -$0.20. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.76% over the week and 4.31% over the month.
Earnings per share for the fiscal year are expected to increase by 13.10%, and -5.48% over the next financial year.
Looking at the support for the AKBA, a number of firms have released research notes about the stock. BTIG Research stated their Buy rating for the stock in a research note on November 29, 2023, with the firm’s price target at $4. H.C. Wainwright coverage for the Akebia Therapeutics Inc. (AKBA) stock in a research note released on August 28, 2023 offered a Buy rating with a price target of $3.75. Piper Sandler was of a view on May 31, 2023 that the stock is Overweight, while Piper Sandler gave the stock Neutral rating on March 31, 2022, issuing a price target of $8- $2. Needham on their part issued Hold rating on March 31, 2022.
